Literature DB >> 25610751

New insights into the mechanism of action of immune checkpoint antibodies.

Aurélien Marabelle1, Holbrook Kohrt2, Ronald Levy2.   

Abstract

Preclinical models have been developed and applied to predict the clinical efficacy of immune checkpoint antibodies. Now these models can be used to dissect the mechanisms by which such immunotherapeutic antibodies work and to build the rationale for combining immune checkpoint-targeting antibodies with potential synergistic activity in cancer patients.

Entities:  

Keywords:  CTLA-4; GITR; OX40; cancer; immune checkpoint antibodies; immunotherapy

Year:  2014        PMID： 25610751      PMCID： PMC4292403          DOI： 10.4161/21624011.2014.954869

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB coengagement in vivo.

Authors:  Fubin Li; Jeffrey V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-11       Impact factor: 11.205

2.  Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.

Authors:  Mark J Selby; John J Engelhardt; Michael Quigley; Karla A Henning; Timothy Chen; Mohan Srinivasan; Alan J Korman
Journal:  Cancer Immunol Res       Date:  2013-04-07       Impact factor: 11.151

3.  Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity.

Authors:  Andrew D Simmons; Marina Moskalenko; Jennifer Creson; Jianmin Fang; Saili Yi; Melinda J VanRoey; James P Allison; Karin Jooss
Journal:  Cancer Immunol Immunother       Date:  2008-01-31       Impact factor: 6.968

4.  T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy.

Authors:  Roch Houot; Ronald Levy
Journal:  Blood       Date:  2008-10-21       Impact factor: 22.113

5.  Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy.

Authors:  Jedd D Wolchok; James P Allison; Dmitriy Zamarin; Rikke B Holmgaard; Sumit K Subudhi; Joon Seok Park; Mena Mansour; Peter Palese; Taha Merghoub
Journal:  Sci Transl Med       Date:  2014-03-05       Impact factor: 17.956

6.  OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy.

Authors:  Yannick Bulliard; Rose Jolicoeur; Jimin Zhang; Glenn Dranoff; Nicholas S Wilson; Jennifer L Brogdon
Journal:  Immunol Cell Biol       Date:  2014-04-15       Impact factor: 5.126

7.  Depleting tumor-specific Tregs at a single site eradicates disseminated tumors.

Authors:  Aurélien Marabelle; Holbrook Kohrt; Idit Sagiv-Barfi; Bahareh Ajami; Robert C Axtell; Gang Zhou; Ranjani Rajapaksa; Michael R Green; James Torchia; Joshua Brody; Richard Luong; Michael D Rosenblum; Lawrence Steinman; Hyam I Levitsky; Victor Tse; Ronald Levy
Journal:  J Clin Invest       Date:  2013-06       Impact factor: 14.808

8.  Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects.

Authors:  Marieke F Fransen; Tetje C van der Sluis; Ferry Ossendorp; Ramon Arens; Cornelis J M Melief
Journal:  Clin Cancer Res       Date:  2013-06-20       Impact factor: 12.531

9.  Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.

Authors:  Tyler R Simpson; Fubin Li; Welby Montalvo-Ortiz; Manuel A Sepulveda; Katharina Bergerhoff; Frederick Arce; Claire Roddie; Jake Y Henry; Hideo Yagita; Jedd D Wolchok; Karl S Peggs; Jeffrey V Ravetch; James P Allison; Sergio A Quezada
Journal:  J Exp Med       Date:  2013-07-29       Impact factor: 14.307

10.  Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies.

Authors:  Yannick Bulliard; Rose Jolicoeur; Maurice Windman; Sarah M Rue; Seth Ettenberg; Deborah A Knee; Nicholas S Wilson; Glenn Dranoff; Jennifer L Brogdon
Journal:  J Exp Med       Date:  2013-07-29       Impact factor: 14.307
  10 in total
  6 in total

1.  A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment.

Authors:  Anje Cauwels; Sandra Van Lint; Geneviève Garcin; Jennyfer Bultinck; Franciane Paul; Sarah Gerlo; José Van der Heyden; Yann Bordat; Dominiek Catteeuw; Lode De Cauwer; Elke Rogge; Annick Verhee; Gilles Uzé; Jan Tavernier
Journal:  Oncoimmunology       Date:  2017-11-27       Impact factor: 8.110

2.  Tetraspanin CD81, a modulator of immune suppression in cancer and metastasis.

Authors:  Felipe Vences-Catalán; Ranjani Rajapaksa; Minu K Srivastava; Aurelien Marabelle; Chiung-Chi Kuo; Ronald Levy; Shoshana Levy
Journal:  Oncoimmunology       Date:  2015-12-18       Impact factor: 8.110

3.  Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells.

Authors:  Paul E Clavijo; Ellen C Moore; Jianhong Chen; Ruth J Davis; Jay Friedman; Young Kim; Carter Van Waes; Zhong Chen; Clint T Allen
Journal:  Oncotarget       Date:  2017-06-11

Review 4.  Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?

Authors:  Laura Rosa Brunet; Thorsten Hagemann; Gayab Andrew; Satvinder Mudan; Aurelien Marabelle
Journal:  Oncoimmunology       Date:  2015-12-18       Impact factor: 8.110

Review 5.  Impact of Depleting Therapeutic Monoclonal Antibodies on the Host Adaptive Immunity: A Bonus or a Malus?

Authors:  Claire Deligne; Benoît Milcent; Nathalie Josseaume; Jean-Luc Teillaud; Sophie Sibéril
Journal:  Front Immunol       Date:  2017-08-14       Impact factor: 7.561

6.  Liposomal TLR9 Agonist Combined with TLR2 Agonist-Fused Antigen Can Modulate Tumor Microenvironment through Dendritic Cells.

Authors:  Kuan-Yin Shen; Hsin-Yu Liu; Wan-Lun Yan; Chiao-Chieh Wu; Ming-Hui Lee; Chih-Hsing Leng; Shih-Jen Liu
Journal:  Cancers (Basel)       Date:  2020-03-28       Impact factor: 6.639
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.